Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Global Anticoagulants Market: Size & Forecast with Impact Analysis of COVID-19 (2021-2025 Edition)Bayer Group, Bristol-Myers Squibb, Boehringher Ingelheim and Daiichi Sankyo are some of the key players operating in the global anticoagulants market, who's Company Profiles has been done in the report.
By: Daedal Research The report also provides an analysis of injectable and oral anticoagulants available in the market. Details of Lovenox, Arixtra, Xarelto, Eliquis, Pradaxa and Savaysa has been provided in the report in terms of their global sales. A brief analysis of the US anticoagulants market has also been provided in terms of value and sales of top four oral anticoagulant drugs in the region. Furthermore, the report also assesses the key opportunities available in the market and outline the market dynamics that are and will be accountable for growth of the industry. Growth of the global anticoagulants market has also been forecasted for the period 2021-2025, taking into consideration previous growth outlines, growth drivers and the existing and forthcoming trends. Region Coverage The US Other Company Coverage Bayer Group Bristol-Myers Squibb Boehringher Ingelheim Daiichi Sankyo Executive Summary Anticoagulants which are also known as blood thinners are drugs that are prescribed to prevent blood from clotting or stop existing clots from getting larger. The drugs prevent harmful clots forming in heart, veins or arteries. Formation of clots in the blood can lead to heart attack or stroke. These drugs are used to treat strokes, myocardial infarctions, pulmonary embolisms, disseminated intravascular coagulation (DIC) and deep vein thrombosis (DVT)- all potentially life-threatening conditions. Anticoagulants work by interrupting the process involved in the formation of blood clots. The most commonly prescribed anticoagulant is Warfarin. Newer types of anticoagulants are also available and are becoming increasingly common. These include rivaroxaban (Xarelto), dabigatran (Pradaxa), apixaban (Eliquis), and edoxaban (Savaysa/Lixiana) Yet, the market faces some challenges which are obstructing the growth of the market. Some of the major challenges are numerous clinical limitations and bleeding risk. For further details, kindly visit : https://www.daedal- Rajeev Kumar (Business Development Manager) Address: 36 SFS Flats Paschim Vihar New Delhi-110063 Mobile: +91-9811715635 Tel: +91-120-4553017 Mail ID - info@daedal- End
Account Email Address Account Phone Number Disclaimer Report Abuse
|